{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:17:28Z","timestamp":1794266248826,"version":"4.9.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute myeloid leukemia (AML) is an aggressive hematological malignancy. Patients with wild-type FLT3 relapsed or refractory (R\/R) AML face significant therapeutic challenges due to the persistent lack of effective treatments. A comprehensive understanding of the mechanisms underlying chemotherapy resistance is needed to the development of effective treatment strategies. Therefore, we investigated the molecular mechanisms underlying cytarabine (Ara-C) resistance and daunorubicin (DNR) tolerance in Ara-C-resistant RHI-1 cells derived from the wild-type FLT3 AML cell line SHI-1. Quantitative analysis of intracellular drug concentrations, proteomics, and phosphoproteomics showed that DNR resistance in Ara-C-resistant RHI-1 cells is driven by metabolic remodeling toward mitochondrial metabolism, upregulation of DNA repair pathways, and enhanced reactive oxygen species (ROS) detoxification rather than reduced drug uptake. Moreover, targeting these compensatory mechanisms, particularly the OXPHOS complex I proteins, significantly improved the efficacy of both Ara-C and DNR. Conclusively, these findings highlight mitochondrial metabolism and DNA repair as critical factors in chemotherapy resistance and offer valuable insights into potential therapeutic targets for enhancing treatment outcomes in patients with wild-type FLT3 R\/R AML.<\/jats:p>","DOI":"10.1038\/s41419-025-07653-6","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:26:00Z","timestamp":1745411160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mechanisms of chemotherapy failure in refractory\/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolism"],"prefix":"10.1038","volume":"16","author":[{"given":"Soo","family":"Yeon Chae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehyun","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Malani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Kallioniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9915-9681","authenticated-orcid":false,"given":"Seung Gyu","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8909-8440","authenticated-orcid":false,"given":"Jong-Seo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-1806","authenticated-orcid":false,"given":"Hugh I.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"7653_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"7653_CR2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","volume":"341","author":"B Lowenberg","year":"1999","unstructured":"Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. New Engl J Med. 1999;341:1051\u201362.","journal-title":"New Engl J Med"},{"key":"7653_CR3","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.3390\/cancers14112806","volume":"14","author":"H Ishii","year":"2022","unstructured":"Ishii H, Yano S. New therapeutic strategies for adult acute myeloid leukemia. Cancers. 2022;14:2806.","journal-title":"Cancers"},{"key":"7653_CR4","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1182\/blood-2005-10-4202","volume":"107","author":"DW Milligan","year":"2006","unstructured":"Milligan DW, Wheatley K, Littlewood T, Craig JIO, Burnett AK. Group ftNHOCS. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006;107:4614\u201322.","journal-title":"Blood"},{"key":"7653_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.leukres.2012.09.016","volume":"37","author":"TA Morris","year":"2013","unstructured":"Morris TA, DeCastro CM, Diehl LF, Gockerman JP, Lagoo AS, Li Z, et al. Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia. Leuk Res. 2013;37:28\u201331.","journal-title":"Leuk Res"},{"key":"7653_CR6","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Network TCGAR.","year":"2013","unstructured":"Network TCGAR. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med. 2013;368:2059\u201374.","journal-title":"New Engl J Med"},{"key":"7653_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ijc.2910260208","volume":"26","author":"S Tsuchiya","year":"1980","unstructured":"Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 1980;26:171\u20136.","journal-title":"Int J Cancer"},{"key":"7653_CR8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/leu.2016.314","volume":"31","author":"D Malani","year":"2017","unstructured":"Malani D, Murumagi A, Yadav B, Kontro M, Eldfors S, Kumar A, et al. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia. 2017;31:1187\u201395.","journal-title":"Leukemia"},{"key":"7653_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"DW Huang","year":"2008","unstructured":"Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2008;37:1\u201313.","journal-title":"Nucleic Acids Res"},{"key":"7653_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330.","journal-title":"Nucleic Acids Res"},{"key":"7653_CR11","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.molmet.2020.02.005","volume":"35","author":"A Siddiqui","year":"2020","unstructured":"Siddiqui A, Ceppi P. A non-proliferative role of pyrimidine metabolism in cancer. Mol Metab. 2020;35:100962.","journal-title":"Mol Metab"},{"key":"7653_CR12","doi-asserted-by":"publisher","first-page":"165759","DOI":"10.1016\/j.bbadis.2020.165759","volume":"1866","author":"S Boukalova","year":"2020","unstructured":"Boukalova S, Hubackova S, Milosevic M, Ezrova Z, Neuzil J, Rohlena J. Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer. Biochimica Et Biophys Acta BBA Mol Basis Dis. 2020;1866:165759.","journal-title":"Biochimica Et Biophys Acta BBA Mol Basis Dis"},{"key":"7653_CR13","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.7150\/jca.54699","volume":"12","author":"R Huang","year":"2021","unstructured":"Huang R, Chen H, Liang J, Li Y, Yang J, Luo C, et al. Dual role of reactive oxygen species and their application in cancer therapy. J Cancer. 2021;12:5543\u201361.","journal-title":"J Cancer"},{"key":"7653_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd2803","volume":"8","author":"D Trachootham","year":"2009","unstructured":"Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov. 2009;8:579\u201391.","journal-title":"Nat Rev Drug Discov"},{"key":"7653_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbcan.2013.12.002","volume":"1845","author":"F Yang","year":"2014","unstructured":"Yang F, Teves SS, Kemp CJ. Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Et Biophys Acta BBA Rev Cancer. 2014;1845:84\u20139.","journal-title":"Biochim Et Biophys Acta BBA Rev Cancer"},{"key":"7653_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","volume":"12","author":"E Christidi","year":"2021","unstructured":"Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021;12:339.","journal-title":"Cell Death Dis"},{"key":"7653_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01483-1","volume":"9","author":"J Zhao","year":"2023","unstructured":"Zhao J, Zhang N, Ma X, Li M, Feng H. The dual role of ferroptosis in anthracycline-based chemotherapy includes reducing resistance and increasing toxicity. Cell Death Discov. 2023;9:184.","journal-title":"Cell Death Discov"},{"key":"7653_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00280-006-0291-9","volume":"59","author":"X Cao","year":"2007","unstructured":"Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol. 2007;59:495\u2013505.","journal-title":"Cancer Chemother Pharmacol"},{"key":"7653_CR19","doi-asserted-by":"publisher","first-page":"BSR20190880","DOI":"10.1042\/BSR20190880","volume":"39","author":"Y Rai","year":"2019","unstructured":"Rai Y, Yadav P, Kumari N, Kalra N, Bhatt AN. Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin. Bioscience Rep. 2019;39:BSR20190880.","journal-title":"Bioscience Rep"},{"key":"7653_CR20","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.tem.2021.07.001","volume":"32","author":"Y Liu","year":"2021","unstructured":"Liu Y, Zhou Q, Song S, Tang S. Integrating metabolic reprogramming and metabolic imaging to predict breast cancer therapeutic responses. Trends Endocrinol Metab. 2021;32:762\u201375.","journal-title":"Trends Endocrinol Metab"},{"key":"7653_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","volume":"23","author":"Y Xie","year":"2016","unstructured":"Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23:369\u201379.","journal-title":"Cell Death Differ"},{"key":"7653_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jpedsurg.2014.01.037","volume":"49","author":"JF Bean","year":"2014","unstructured":"Bean JF, Qiu Y-Y, Yu S, Clark S, Chu F, Madonna MB. Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma. J Pediatr Surg. 2014;49:981\u20134.","journal-title":"J Pediatr Surg"},{"key":"7653_CR23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00018-019-03299-8","volume":"77","author":"A Klinakis","year":"2020","unstructured":"Klinakis A, Karagiannis D, Rampias T, Targeting DNA. repair in cancer: current state and novel approaches. Cellular Mol Life Sci. 2020;77:677\u2013703.","journal-title":"Cellular Mol Life Sci"},{"key":"7653_CR24","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.3390\/ijms21113934","volume":"21","author":"M Kciuk","year":"2020","unstructured":"Kciuk M, Bukowski K, Marciniak B, Kontek R. Advances in DNA repair\u2014emerging players in the arena of eukaryotic DNA repair. Int J Mol Sci. 2020;21:3934.","journal-title":"Int J Mol Sci"},{"key":"7653_CR25","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41418-019-0393-7","volume":"27","author":"P-H Chen","year":"2020","unstructured":"Chen P-H, Wu J, Ding C-KC, Lin C-C, Pan S, Bossa N, et al. Kinome screen of ferroptosis reveals a novel role of ATM in regulating iron metabolism. Cell Death Differ. 2020;27:1008\u201322.","journal-title":"Cell Death Differ"},{"key":"7653_CR26","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/sj.leu.2402876","volume":"17","author":"K Davison","year":"2003","unstructured":"Davison K, C\u00f4t\u00e9 S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia. 2003;17:931\u201340.","journal-title":"Leukemia"},{"key":"7653_CR27","doi-asserted-by":"publisher","first-page":"9613090","DOI":"10.1155\/2019\/9613090","volume":"2019","author":"A Nandi","year":"2019","unstructured":"Nandi A, Yan L-J, Jana CK, Das N. Role of catalase in oxidative stress- and age-associated degenerative diseases. Oxidative Med Cell Longev. 2019;2019:9613090.","journal-title":"Oxidative Med Cell Longev"},{"key":"7653_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/cancers16010008","volume":"16","author":"F Selheim","year":"2024","unstructured":"Selheim F, Aaseb\u00f8 E, Bruserud \u00d8, Hernandez-Valladares M. High mitochondrial protein expression as a potential predictor of relapse risk in acute myeloid leukemia patients with the monocytic FAB subtypes M4 and M5. Cancers. 2024;16:8.","journal-title":"Cancers"},{"key":"7653_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41375-022-01796-7","volume":"37","author":"S Stratmann","year":"2023","unstructured":"Stratmann S, Vesterlund M, Umer HM, Eshtad S, Skaftason A, Herlin MK, et al. Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children. Leukemia. 2023;37:550\u20139.","journal-title":"Leukemia"},{"key":"7653_CR30","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/s41375-020-01050-y","volume":"35","author":"HC Murray","year":"2021","unstructured":"Murray HC, Enjeti AK, Kahl RGS, Flanagan HM, Sillar J, Skerrett-Byrne DA, et al. Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia. Leukemia. 2021;35:1782\u20137.","journal-title":"Leukemia"},{"key":"7653_CR31","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/nrc3985","volume":"15","author":"A Chalkiadaki","year":"2015","unstructured":"Chalkiadaki A, Guarente L. The multifaceted functions of sirtuins in cancer. Nat Rev Cancer. 2015;15:608\u201324.","journal-title":"Nat Rev Cancer"},{"key":"7653_CR32","doi-asserted-by":"publisher","first-page":"9732","DOI":"10.1021\/acs.jmedchem.1c00601","volume":"64","author":"F Fiorentino","year":"2021","unstructured":"Fiorentino F, Mai A, Rotili D. Emerging therapeutic potential of SIRT6 modulators. J Med Chem. 2021;64:9732\u201358.","journal-title":"J Med Chem"},{"key":"7653_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40170-021-00240-1","volume":"9","author":"P Becherini","year":"2021","unstructured":"Becherini P, Caffa I, Piacente F, Damonte P, Vellone VG, Passalacqua M, et al. SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice. Cancer Metab. 2021;9:6.","journal-title":"Cancer Metab"},{"key":"7653_CR34","doi-asserted-by":"publisher","first-page":"11021","DOI":"10.1074\/jbc.REV120.011438","volume":"295","author":"MA Klein","year":"2020","unstructured":"Klein MA, Denu JM. Biological and catalytic functions of sirtuin 6 as targets for small-molecule modulators. J Biol Chem. 2020;295:11021\u201341.","journal-title":"J Biol Chem"},{"key":"7653_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep45465","volume":"7","author":"S Heinz","year":"2017","unstructured":"Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G, Ellinger-Ziegelbauer H. Mechanistic investigations of the mitochondrial complex i inhibitor rotenone in the context of pharmacological and safety evaluation. Sci Rep. 2017;7:45465.","journal-title":"Sci Rep"},{"key":"7653_CR36","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519\u201330.","journal-title":"J Gen Physiol"},{"key":"7653_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cmet.2020.09.001","volume":"32","author":"D Forte","year":"2020","unstructured":"Forte D, Garc\u00eda-Fern\u00e1ndez M, S\u00e1nchez-Aguilera A, Stavropoulou V, Fielding C, Mart\u00edn-P\u00e9rez D, et al. Bone marrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy. Cell Metab. 2020;32:829\u201343.e9.","journal-title":"Cell Metab"},{"key":"7653_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","volume":"36","author":"L de Beauchamp","year":"2022","unstructured":"de Beauchamp L, Himonas E, Helgason GV. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2022;36:1\u201312.","journal-title":"Leukemia"},{"key":"7653_CR39","doi-asserted-by":"publisher","first-page":"eaax2863","DOI":"10.1126\/scitranslmed.aax2863","volume":"11","author":"D Sharon","year":"2019","unstructured":"Sharon D, Cathelin S, Mirali S, Di Trani JM, Yanofsky DJ, Keon KA, et al. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response. Sci Transl Med. 2019;11:eaax2863.","journal-title":"Sci Transl Med"},{"key":"7653_CR40","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24:1859\u201366.","journal-title":"Nat Med"},{"key":"7653_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"7653_CR42","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.bbabio.2006.11.018","volume":"1767","author":"PM Herst","year":"2007","unstructured":"Herst PM, Berridge MV. Cell surface oxygen consumption: a major contributor to cellular oxygen consumption in glycolytic cancer cell lines. Biochimica et Biophysica Acta (BBA). Bioenergetics. 2007;1767:170\u20137.","journal-title":"Bioenergetics"},{"key":"7653_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1039\/a809656b","volume":"36","author":"H Tominaga","year":"1999","unstructured":"Tominaga H, Ishiyama M, Ohseto F, Sasamoto K, Hamamoto T, Suzuki K, et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun. 1999;36:47\u201350.","journal-title":"Anal Commun"},{"key":"7653_CR44","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/s41596-018-0006-9","volume":"13","author":"P Mertins","year":"2018","unstructured":"Mertins P, Tang LC, Krug K, Clark DJ, Gritsenko MA, Chen L, et al. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography\u2013mass spectrometry. Nat Protoc. 2018;13:1632\u201361.","journal-title":"Nat Protoc"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07653-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07653-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07653-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T10:02:42Z","timestamp":1748253762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07653-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7653"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07653-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article the funding section has been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"331"}}